Skip to main content
EVAX
NASDAQ Life Sciences

Evaxion A/S Grants Warrants Potentially Exceeding Current Market Cap Value

Analysis by Arik Shkolnikov
Sentiment info
Negative
Importance info
9
Price
$3.16
Mkt Cap
$20.529M
52W Low
$1.2
52W High
$12.15
Market data snapshot near publication time

summarizeSummary

Evaxion A/S granted over 9 million warrants to insiders and consultants with very low exercise prices, representing a potential value upon exercise greater than the company's current market capitalization.


check_boxKey Events

  • Significant Warrant Grants

    The company's board of directors granted an aggregate of 9,044,725 warrants in two tranches on February 5 and February 16, 2026.

  • Recipients Include Insiders and Consultants

    Warrants were granted to board members, management, employees, and advisors/consultants.

  • Highly Favorable Exercise Prices

    The warrants have exercise prices of $0.087 and $0.115 per ordinary share, significantly below the current stock price of $3.16.

  • Substantial Potential Dilution

    If all warrants were exercised, it would result in a potential dilution of approximately 2.17% of the current outstanding shares. The implied value of the shares underlying these warrants, if exercised and sold at the current market price, would exceed the company's current market capitalization.


auto_awesomeAnalysis

The grant of 9,044,725 warrants to board members, management, employees, and consultants, with exercise prices of $0.087 and $0.115 per share, introduces substantial potential dilution. While the direct share dilution is approximately 2.17% of current outstanding shares, the implied value of these shares if exercised and sold at the current market price of $3.16 would exceed the company's entire market capitalization. This indicates a significant transfer of potential value to warrant holders, which is highly dilutive for existing shareholders. The low exercise prices make these warrants deeply in-the-money, providing a strong incentive for exercise.

At the time of this filing, EVAX was trading at $3.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $20.5M. The 52-week trading range was $1.20 to $12.15. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed EVAX - Latest Insights

EVAX
May 12, 2026, 9:30 AM EDT
Filing Type: 6-K
Importance Score:
7
EVAX
May 07, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
EVAX
Apr 27, 2026, 8:10 AM EDT
Filing Type: 6-K
Importance Score:
7
EVAX
Apr 22, 2026, 7:00 AM EDT
Filing Type: 6-K
Importance Score:
9
EVAX
Apr 17, 2026, 3:30 PM EDT
Filing Type: 6-K
Importance Score:
8
EVAX
Apr 17, 2026, 3:20 PM EDT
Filing Type: 6-K
Importance Score:
7
EVAX
Apr 17, 2026, 3:00 PM EDT
Source: GlobeNewswire
Importance Score:
7
EVAX
Apr 07, 2026, 8:05 AM EDT
Filing Type: 6-K
Importance Score:
7
EVAX
Mar 30, 2026, 8:05 AM EDT
Filing Type: 6-K
Importance Score:
8
EVAX
Mar 19, 2026, 9:00 AM EDT
Filing Type: 6-K
Importance Score:
9